Bacteria	Conditions	Phage Treatments	Administration Route	Clinical Trial or Study Link
Escherichia coli	Crohn's Disease	EcoActive Phage	Orally	Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
	Urinary Tract Infection	LBP-EC01	Intrurethral and intravenous	A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
	Urinary Tract Infection	PYO phage	Intravescial instillation	Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate
	Venous Leg Ulcers	WPP201	Topically	Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers
	Testing in healthy subjects for e. coli infections	SNIPR001	Orally	A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
Staphylococcus aureus	Bacteremia	AP-SA02	Intravenously	Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects with S. Aureus Bacteremia (diSArm)
	Improving gut health for healthy volunteers	AB-SA01 (10^8 or 10^ PFU/phage)	Topically on skin	Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults
	Prosthetic Joint Infection	PP1493 or PP1815	Suspension, single intra-articular injection	Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated with DAIR
	Atopic Dermatitis	BX005-A	Topically	A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
Mycobacterium tuberculosis	Tuberculosis	Phase-based assay diagnostic test to lyse mycobacterial cells for detection of DNA or antigens	N/A	Rapid Research in Diagnostics Development for TB Network (R2D2TB Network)
Pseudomonas aeruginosa	Cystic Fibrosis	WRAIR-PAM-CF1 bacteriophage	Intravenously	A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized with Pseudomonas Aeruginosa
	Cystic Fibrosis	YPT-01	Inhalation	CYstic Fibrosis bacteriPHage Study at Yale (CYPHY)
	Diabetic Foot Infection	TP-102	Topically	Bacteriophage Therapy TP-102 in Patients with Diabetic Foot Infection (REVERSE2)
	Cystic Fibrosis	BX004-A	Inhalation	Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
Klebsiella Pneumoniae	Inflammatory Bowel Disease (IBD)	BX002-A	Orally in liquid form	A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults
	UTI	Mineola (MH333064) as part of 3-phage cocktail	Intravenously	Therapeutic Potential of Intravenous Phage as Standalone Therapy for Recurrent Drug-Resistant Urinary Tract Infections
Enterococci	Vancomycin-resistant Enterocci in gastrointestianal tract	VRElysin	Orally	Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects